Montana et al. [90] have shown how signals such as bradykinin promote the chemotactic attraction and invasion of glioma cells that express bradykinin 2 receptors (B2R), proposing a B2R antagonist as a future anti-invasive drug approach in glioma therapy. Here, BDKRB2 is linked to glioma.